Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 4, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Digital Ulcers in Systemic Sclerosis
Interventions
DRUG

TOP-N53

TOP-N53 solution (IMP) containing 80 µg/ml TOP-N53 is applied topically directly to the digital ulcer of patients with systemic sclerosis. The dose if defined by volume and exposure time of the IMP.

DRUG

Sildenafil

Parallel treatment with Sildenafil 20 mg 3-times per day is permitted if patient has been on a stable dose for 2 weeks prior to screening.

DRUG

TOP-N53 vehicle

TOP-N53 vehicle solution will be topically applied to digital ulcers of systemic sclerosis patients.

Trial Locations (2)

75014

RECRUITING

AP-HP Hôpital Cochin, Paris

38 700

RECRUITING

CHU Grenoble Alpes, La Tronche

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bioskin GmbH

INDUSTRY

lead

Topadur Pharma AG

INDUSTRY

NCT06954597 - Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis | Biotech Hunter | Biotech Hunter